Translational Development Acquisition (TDAC) Stock Price, News & Analysis
What Changed
Price Move History
- Daily moves over 5%
- 0 169 sessions, September 10, 2025 to September 11, 2026
- Largest daily move
- +0.9% close of July 28, 2026
- 1-year change
- +5% closing prices, September 10, 2025 to September 11, 2026
- 5-year change
- -8.8% closing prices, September 10, 2021 to September 11, 2026
Company Description
Translational Development Acquisition (NASDAQ: TDAC) is classified in the shell companies industry within the Financial Services sector and carries a market capitalization of $209.7M.
TDAC has gained 5.0% over the past year. The last closing price was $10.86.
For FY2025, Translational Development Acquisition reported net income of $6.4M.
This page collects what Stock Titan holds for TDAC, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Translational Development Acquisition (TDAC) closed at $10.86 on September 11, 2026. Over the past 12 months, the price has gained 5.0%.
TDAC Metrics & Rankings
Price returns through September 11, 2026. Month-to-date and YTD include the first trading day. Ranking links may use different dates.
Latest News
Translational Development Acquisition has 10 recent news articles. Of the recent coverage, 4 articles coincided with positive price movement and 4 with negative movement. Key topics include acquisition. View all TDAC news →
SEC Filings
Translational Development Acquisition has filed 5 recent SEC filings, including 2 Form SCHEDULE 13G/A, 1 Form 425, 1 Form 10-Q, 1 Form SCHEDULE 13G. The most recent filing was submitted on August 14, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all TDAC SEC filings →
Financial Highlights
operating income reached -$945K, and net income was $6.4M. The company generated -$608K in operating cash flow. With a current ratio of 0.07, short-term liquidity bears monitoring.
Upcoming Events
Short Interest History
Short interest in Translational Development Acquisition (TDAC) currently stands at 36.1 thousand shares, down 6.8% from the previous reporting period, representing 0.2% of the float. Since September 2025, short interest has increased by 12975.4%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Translational Development Acquisition (TDAC) currently stands at 1.0 days. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The ratio has shown significant volatility over the period, ranging from 1.0 to 20.8 days.
TDAC Company Profile & Sector Positioning
Translational Development Acquisition (TDAC) operates in the Shell Companies industry within the broader Financial Services sector and is listed on the NASDAQ.
Investors comparing TDAC often look at related companies in the same sector, including Real Asset Acquisition Corp. (RAAQ), Helix Acquisition Corp. II (HLXB), Sanaby Health (SANB), Melar Acquisition Corp. I (MACI), and Larkspur Health Acquisition Corp (LSPR). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate TDAC's relative position within its industry.